Alzheimer’s disease
Sanofi completes acquisition of Vigil Neuroscience to early neurology pipeline
August 6, 2025Mergers and Acquisitions Alzheimer's disease, Corporate, Neurology, Sanofi, Vigil Neuroscience, neurodegenerative diseases
Sanofi has announced that it has finalised its acquisition of Vigil Neuroscience, a US-based biotechnology company specialising in neurodegenerative diseases. …
Roche receives CE Mark for blood test to help rule out Alzheimer’s
July 30, 2025Research and Development Alzheimer's disease, CE Mark approval, Eli Lilly, Neurology, Roche
Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in vitro diagnostic regulation-certified blood-based diagnostic …
Sanofi to acquire Vigil Neuroscience, adding Alzheimer’s disease candidate to early-stage pipeline
May 23, 2025Mergers and Acquisitions, Research and Development Alzheimer's disease, Neurology, Sanofi, Vigil Neuroscience, neurodegenerative diseases
Sanofi has announced an agreement to acquire Vigil Neuroscience, a biotech company focused on therapies for neurodegenerative diseases. The deal …
Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months
April 10, 2025Research and Development Alzheimer's disease, Neurology, TauRx Pharmaceutics, research and development
TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the progression of Alzheimer’s disease over …
AC Immune’s pTau-targeting immunotherapy awarded Fast Track designation by FDA
July 26, 2024Research and Development AC Immune, Alzheimer's disease, Neurology, clinical trials, fast track designation, immunotherapy, tau protein
Clinical-stage biopharmaceutical company AC Immune announced that the US Food and Drug Administration (FDA) has granted its Alzheimer’s disease (AD) …
Nxera Pharma partner Neurocrine Biosciences enters phase 1 NBI-1117567 study
May 9, 2024Research and Development Alzheimer's disease, Neurocrine Biosciences, Neurology, Nxera Pharma, Parkinson's disease, clinical trials, dementia, schizophrenia
Nxera Pharma’s neuroscience-focused biopharmaceutical partner  Neurocrine Biosciences has announced it has successfully started its phase 1, first-in-human trial of investigational …
PharmaKure and Universiti Teknologi MARA (UiTM) partner for Alzheimer’s diagnosis research
December 13, 2023Medical Communications Alzheimer's disease, Neurology, PharmaKure, UiTM
PharmaKure and the faculty of pharmacy at the University Teknologi MARA (UiTM), Malaysia, have announced a research collaboration focusing on …
Halozyme and Acumen Pharmaceuticals enter collaboration for Alzheimer’s treatment
November 7, 2023Business Services Acumen Pharmaceuticals, Alzheimer's disease, Halozyme, Neurology, collaboration
Halozyme Therapeutics has announced a global collaboration and non-exclusive license with Acumen Pharmaceuticals, providing Acumen with access to Halozyme’s Enhanze …
Allyx Therapeutics shares phase 1a trial data for Alzheimer’s treatment
October 31, 2023Medical Communications Allyx Therpeutics, Alzheimer's disease, Neurology, clinical trial
Allyx Therapeutics has announced phase 1a single ascending dose study results at the 16th Clinical Trials on Alzheimer’s Disease (CTAD) …
Alnylam shares positive results from phase 1 trial
July 17, 2023Research and Development ALN-APP, Alnylam, Alzheimer's disease, Cerebral Amyloid Angiopathy, Neurology, clinical trial
Alnylam Pharmaceuticals has announced positive interim results for the ongoing single ascending dose section of its phase 1 study of …
FDA grants Alzheimer’s disease drug Leqembi full approval
July 7, 2023Medical Communications Alzheimer's disease, Biogen, Eisai, FDA, Neurology
Japanese pharmaceutical company Eisai and US-based biotechnology company Biogen have announced that the US Food and Drug Administration (FDA) has …
Eli Lilly shares positive results from phase 3 study of donanemab for early Alzheimer’s disease
May 5, 2023Research and Development Alzheimer's disease, Eli Lilly, Neurology, clinical trial, new drug
Eli Lilly has announced positive results from the TRAILBLAZER-ALZ 2 phase 3 trial assessing donanemab’s ability to slow cognitive and …
Eisai and Biogen’s Alzheimer’s drug slows progression in Phase 2 trials
July 26, 2018Research and Development Alzheimer's disease, BAN2401, Biodgen, Eisai, phase 2, research
An experimental drug developed by the Massachusetts-based multinational Biogen and their Japanese partner Eisai has been shown to significantly slow …
Alzheimer’s protein treatment that works in human cells
April 12, 2018Research and Development Alzheimer's disease, Gladstone Institutes, biotech, drugs, pharma, pharmaceutical
One of the major stumbling blocks that science has come up against, when trying to develop potential treatments for Alzheimer’s …
Antiepileptic drug use linked to increased risk of Alzheimer’s and dementia
April 10, 2018Manufacturing and Production, Research and Development Alzheimer's disease, dementia, epilepsy, pharma
A new study conducted at the University of Eastern Finland and the German Center for Neurodegenerative Diseases (DZNE) has revealed …
Latest content
Five Facts about cardiovascular disease
